دورية أكاديمية

The A to I editing landscape in melanoma and its relation to clinical outcome

التفاصيل البيبلوغرافية
العنوان: The A to I editing landscape in melanoma and its relation to clinical outcome
المؤلفون: Austeja Amweg, Marina Tusup, Phil Cheng, Ernesto Picardi, Reinhard Dummer, Mitchell P Levesque, Lars E French, Emmanuella Guenova, Severin Läuchli, Thomas Kundig, Mark Mellett, Steve Pascolo
المصدر: RNA Biology, Vol 19, Iss 1, Pp 996-1006 (2022)
بيانات النشر: Taylor & Francis Group, 2022.
سنة النشر: 2022
المجموعة: LCC:Genetics
مصطلحات موضوعية: adar, a-to-i editing, alu sequences, editing, melanoma, immune checkpoint inhibitors, immunotherapy, Genetics, QH426-470
الوصف: RNA editing refers to non-transient RNA modifications that occur after transcription and prior to translation by the ribosomes. RNA editing is more widespread in cancer cells than in non-transformed cells and is associated with tumorigenesis of various cancer tissues. However, RNA editing can also generate neo-antigens that expose tumour cells to host immunosurveillance. Global RNA editing in melanoma and its relevance to clinical outcome currently remain poorly characterized. The present study compared RNA editing as well as gene expression in tumour cell lines from melanoma patients of short or long metastasis-free survival, patients relapsing or not after immuno- and targeted therapy and tumours harbouring BRAF or NRAS mutations. Overall, our results showed that NTRK gene expression can be a marker of resistance to BRAF and MEK inhibition and gives some insights of candidate genes as potential biomarkers. In addition, this study revealed an increase in Adenosine-to-Inosine editing in Alu regions and in non-repetitive regions, including the hyperediting of the MOK and DZIP3 genes in relapsed tumour samples during targeted therapy and of the ZBTB11 gene in NRAS mutated melanoma cells. Therefore, RNA editing could be a promising tool for identifying predictive markers, tumour neoantigens and targetable pathways that could help in preventing relapses during immuno- or targeted therapies.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1547-6286
1555-8584
15476286
العلاقة: https://doaj.org/toc/1547-6286Test; https://doaj.org/toc/1555-8584Test
DOI: 10.1080/15476286.2022.2110390
الوصول الحر: https://doaj.org/article/d73ba5df73fb42d888ad2fe4592ab9acTest
رقم الانضمام: edsdoj.73ba5df73fb42d888ad2fe4592ab9ac
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:15476286
15558584
DOI:10.1080/15476286.2022.2110390